Harkanwal Dhillon, MD
Nephrology · Cuyahoga Falls, OHNPI 1538327721
Payments from drug & device makers
Across 59 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$254
- AstraZeneca$169
- Otsuka America Pharmaceutical, Inc.$151
- Fresenius USA Marketing, Inc.$103
- Akebia Therapeutics Inc$87
- Aurinia Pharma U.S., Inc.$60
- plus $250 from 9 others
What the payments were for
- Food & beverage$1,03696%
- Education$394%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 10 | $254 |
| AstraZeneca | 12 | $169 |
| Otsuka America Pharmaceutical, Inc. | 8 | $151 |
| Fresenius USA Marketing, Inc. | 6 | $103 |
| Akebia Therapeutics Inc | 7 | $87 |
| Aurinia Pharma U.S., Inc. | 3 | $60 |
| Mallinckrodt Enterprises LLC | 2 | $45 |
| Amgen(2 entities) | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Shire North American Group Inc | 1 | $23 |
| Baxter Healthcare | 1 | $20 |
| Genentech USA, Inc. | 1 | $17 |
| Calliditas Therapeutics US Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 1 | $16 |
How this compares
$1,075 in reported general payments places this provider in the 45th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lanthanum Carbonate | 31 | $17,881 |
| Sevelamer Carbonate | 34 | $6,680 |
| Calcium Acetate | 26 | $4,592 |
| Atovaquone | 11 | $2,094 |
| Calcitriol | 77 | $1,343 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 23 | $1,193 |
| Hydralazine Hcl | 57 | $1,037 |
| Midodrine Hcl | 28 | $852 |
| Furosemide | 53 | $789 |
| Losartan Potassium | 39 | $442 |
| Carvedilol | 37 | $352 |
| Spironolactone | 24 | $350 |
| Amlodipine Besylate | 31 | $342 |
| Lisinopril | 28 | $303 |
| Torsemide | 17 | $292 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Cuyahoga Falls
- Isabelle AyoubColumbus$1.6M
- Andrew LazarBeachwood$806K
- Samir ParikhColumbus$699K
- Brad RovinColumbus$625K
- Lance DworkinToledo$601K
- Mohamed SekkarieToledo$524K
- Kevin SchroederColumbus$518K
- Prabir Roy ChaudhuryCincinnati$483K
- Amit GovilCincinnati$444K
- Sankar NavaneethanCleveland$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.